Statins do not decrease small, dense low-density lipoprotein

Area of Science:

• Cardiovascular Medicine
• Lipidology
• Pharmacology

Background:

• Low-density lipoprotein (LDL) subfractions are increasingly recognized as important in cardiovascular risk assessment.
• Statins are primary lipid-lowering drugs, but their precise effects on LDL subfractions require further elucidation.
• Small, dense LDL particles are considered more atherogenic than large, buoyant LDL particles.

Purpose of the Study:

• To investigate the impact of statin therapy on the proportion of small, dense LDL particles in patients with and without coronary artery disease.
• To compare LDL subfraction profiles between statin-treated patients and a control group.

Main Methods:

• Observational study involving 612 patients, stratified into statin-treated (n=172) and control (n=440) groups.
• Density-gradient ultracentrifugation was used to measure LDL subfractions.
• Patients were further subdivided based on the presence or absence of coronary artery disease.

Main Results:

• Statin treatment significantly lowered total cholesterol, LDL cholesterol, apolipoprotein B, and the LDL cholesterol/apolipoprotein B ratio.
• The proportion of small, dense LDL was significantly higher in the statin group (42.9% ± 9.5%) compared to the control group (41.3% ± 8.5%; P=0.046).
• The proportion of large, buoyant LDL was lower in the statin group (23.6% ± 7.5%) compared to the control group (25.4% ± 7.9%; P=0.011).

Conclusions:

• Statin therapy increases the proportion of small, dense LDL particles, irrespective of coronary artery disease status.
• While statins reduce overall LDL cholesterol and absolute amounts of LDL subfractions, they appear to shift the LDL profile towards smaller, denser particles.
• Further research is warranted to confirm these findings and explore the implications for atherogenesis and atherosclerosis progression.